The U.S. health regulator said on April 5 GlaxoSmithKline and Vir Biotechnology’s antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.
Regeneron Pharmaceuticals Inc. on Feb. 4 reported fourth-quarter 2021 revenue that beat analysts’ estimates, boosted by demand for the blockbuster drugs Dupixent and Eylea, coupled with higher sales of the company’s COVID-19 therapy.
German researchers found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus, likely reducing treatment options if the new variant prevails.
New mutations, or variants, of the SARS-CoV-2 virus that causes Covid-19 are continuing to be discovered. Health officials in Florida cited a new mutation of the Brazilian strain (P.1) that they are calling P2 or P.1.1.
Europe’s drug regulator is evaluating South Korean drugmaker Celltrion’s Covid-19 antibody treatment, the third such drug against the disease to go under real-time review in the region.
